NOVOLIN R
(Human insulin)ApprovedSmall molecule
Novo NordiskNOVOLIN R is one of 237 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
8
Indications
40
Total Trials
3
Active Trials
236
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskApproved
Synthroid
IInstitut Jerome Lejeune
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes9 trials
Show 6 more trials
Type 2 Diabetes5 trials
Concentration2 trials
Insulin resistance2 trials
20 more indications
Gestational Diabetes1 trial
Insulin Sensitivity1 trial
Adolescent1 trial
Type 2 Diabetes Mellitus1 trial
Observational Study1 trial
Type 2 Diabetic Patients1 trial
ESS1 trial
AIN1 trial
Pemphigus1 trial
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
Completed·—·Phase 2·NCT07461103·20 enrolled
Sympathetic Activity1 trial
Prospective1 trial
Diabetes Mellitus1 trial
Overweight1 trial
Regulatory
FDA Approval Timeline[4]
Jun 25, 1991
NOVOLIN R
BLA BLA019938
Jun 25, 1991
NOVOLIN 70/30
BLA BLA019991
Jul 1, 1991
NOVOLIN N
BLA BLA019959
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Human insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company